Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan;30(1):5-15.
doi: 10.1111/hae.14907. Epub 2023 Dec 18.

Gene therapy for haemophilia A and B, from basic principles to clinical implementation: An illustrated review

Cihan Ay  1 , Laurent Frenzel  2   3 , Karen Pinachyan  4 , Sandra Le Quellec  4
Affiliations
Review

Gene therapy for haemophilia A and B, from basic principles to clinical implementation: An illustrated review

Cihan Ay et al. Haemophilia. 2024 Jan.

Abstract

Introduction: With recent approval of the first two gene therapies for haemophilia A and B, educational materials about AAV-based gene therapy are needed by the haemophilia community for a better understanding of this novel therapeutic approach and helping healthcare providers and patients making personalized choices amongst an increasing array of therapeutic options.

Aim: To provide a comprehensive summary of the whole process of AAV-based gene therapy from basic principles to clinical implementation through an illustrated review.

Methods: The authors, with expertise in and knowledge about gene therapy for haemophilia A and B, reviewed relevant articles from PubMed database and translated them into illustrations.

Results: The review is divided into eight illustrated sections providing an overview of gene therapy for haemophilia A and B from haemophilia basics and current treatment landscape, principles of the AAV-based liver-directed gene therapy, through exploring the efficacy and safety results of published phase III clinical trials, current and future challenges, to implementation in clinical practice, including the hub and spoke models and the patient journey.

Conclusion: This illustrated review educates healthcare professionals on AAV-based gene therapy for haemophilia A and B enabling them to further educate their peers and their patients.

Keywords: AAV; bleeds; factor IX; factor VIII; gene therapy; haemophilia.

PubMed Disclaimer

References

REFERENCES

    1. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood. 1998;92(11):3983-3996.
    1. Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K. Complete nucleotide sequences of the gene for human factor IX (antihemophilic factor B). Biochemistry. 1985;24(14):3736-3750.
    1. Shahani T, Covens K, Lavend'homme R, et al. Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII. J Thromb Haemost. 2014;12(1):36-42.
    1. Tatsumi K, Ohashi K, Mukobata S, et al. Hepatocyte is a sole cell type responsible for the production of coagulation factor IX in vivo. Cell Med. 2012;3(1-3):25-31.
    1. Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540-546.

LinkOut - more resources